Prognostic impact of DDX41 germline mutations in intensively treated acute myeloid leukemia patients: an ALFA-FILO study

MLA

Duployez, Nicolas, et al. “Prognostic Impact of DDX41 Germline Mutations in Intensively Treated Acute Myeloid Leukemia Patients: An ALFA-FILO Study.” Blood, vol. 140, no. 7, Aug. 2022, pp. 756–68. EBSCOhost, https://doi.org/10.1182/blood.2021015328.

APA

Duployez, N., Largeaud, L., Duchmann, M., Kim, R., Rieunier, J., Lambert, J., Bidet, A., Larcher, L., Lemoine, J., Delhommeau, F., Hirsch, P., Fenwarth, L., Kosmider, O., Decroocq, J., Bouvier, A., Le Bris, Y., Ochmann, M., Santagostino, A., Adès, L., … Sébert, M. (2022). Prognostic impact of DDX41 germline mutations in intensively treated acute myeloid leukemia patients: an ALFA-FILO study. Blood, 140(7), 756–768. https://doi.org/10.1182/blood.2021015328

Chicago

Duployez, Nicolas, Laëtitia Largeaud, Matthieu Duchmann, Rathana Kim, Julie Rieunier, Juliette Lambert, Audrey Bidet, et al. 2022. “Prognostic Impact of DDX41 Germline Mutations in Intensively Treated Acute Myeloid Leukemia Patients: An ALFA-FILO Study.” Blood 140 (7): 756–68. doi:10.1182/blood.2021015328.